New migraine treatment guidelines released by ACP

This week’s healthcare news highlights important updates for providers. Key topics include new migraine treatment guidelines, advancements in diabetes care, and significant FDA approvals. The American College of Physicians (ACP) released new recommendations for treating acute episodic migraines. They suggest using a triptan alongside nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen for patients with moderate to severe headaches. The guideline emphasizes starting this combination therapy as soon as a migraine begins. In diabetes care, a study showed that automated insulin delivery (AID) using Tandem Diabetes Care’s Control-IQ+ technology is more effective than continuous glucose monitoring (CGM) alone for adults with type 2 diabetes. After 13 weeks, patients using AID had a 0.9% reduction in hemoglobin A1c levels, compared to a 0.3% drop in those using CGM only. Additionally, the FDA approved new treatments for several health conditions. These approvals are important for patients with Crohn’s disease, C3 glomerulopathy, and transthyretin amyloid cardiomyopathy (ATTR-CM). These developments are crucial for healthcare providers to stay informed about evolving treatment options and guidelines.